Haihong Shi
Chongqing University of Posts and Telecommunications(CN)Guizhou Normal University(CN)Pfizer (United States)(US)Nantong University(CN)Affiliated Hospital of Nantong University(CN)
Publications by Year
Research Areas
Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, SARS-CoV-2 and COVID-19 Research, PARP inhibition in cancer therapy, Computational Drug Discovery Methods
Most-Cited Works
- → Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir(2022)153 cited
- → Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment(2022)65 cited
- → Calculation of embodied energy in Sino-USA trade: 1997–2011(2014)53 cited
- → Ultrasmall Au and Ag Nanoclusters for Biomedical Applications: A Review(2020)50 cited
- → A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir(2024)50 cited
- → The use of chemical derivatization to enhance liquid chromatography/tandem mass spectrometric determination of 1‐hydroxypyrene, a biomarker for polycyclic aromatic hydrocarbons in human urine(2005)46 cited